查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1829931

2025年全球乳癌液态切片市场报告

Breast Cancer Liquid Biopsy Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

近年来，乳癌液态切片市场规模迅速扩张，从2024年的7.8亿美元成长到2025年的8.9亿美元，复合年增长率为14.2%。预测期内的成长归因于次世代定序(NGS) 的进步、乳癌盛行率的上升、对非侵入性诊断的需求不断增长、个人化医疗的普及以及癌症研究资金的增加。

预计未来几年乳癌液态切片市场将快速成长，到2029年将达到15.3亿美元，复合年增长率为14.5%。预测期内的成长动力包括：液态切片检测技术的进步、液态切片在早期癌症筛检中的应用日益广泛、对即时癌症监测的需求不断增长、精准肿瘤学应用的不断扩展以及对液态切片研发投入的不断增加。预测期内的主要趋势包括：人工智慧在液态切片分析中的整合、单细胞测序的进步、多体学液态切片平台的开发、液态切片灵敏度和特异性的提高，以及数位PCR在超精准突变检测中的应用。

乳癌液态切片是一种微创测试，可检测和分析患者血液和其他体液中的肿瘤衍生物质，无需进行传统的切片检查即可提供乳癌的存在、进展和遗传特征的宝贵见解。

乳癌液态切片的主要产品包括耗材和套件。耗材是指用于检测和分析乳癌相关生物标记的液态切片试验的一次性材料、试剂和试剂套件。关键生物标记包括细胞外囊泡（EV）、游离DNA（cfDNA）、循环肿瘤RNA（ctRNA）、循环性肿瘤细胞（CTC）和游离RNA（cfRNA）。这些生物标记用于早期检测、筛检和诊断。乳癌液态切片的最终用户包括研究实验室、医院、医生实验室、参考实验室、公共卫生实验室、研究机构、小分子实验室和病理实验室。

2025年春季美国关税的突然上调及其引发的贸易摩擦对医疗设备行业产生了重大影响，尤其对用于诊断影像设备的进口零件、手术用不銹钢和一次性塑胶製品产生了重大影响。由于医院和诊所抵制涨价，製造商面临利润压力。监管挑战使情况更加复杂，因为由于关税而更换供应商通常需要医疗设备重新认证，导致市场进入延迟。为此，企业正在透过双重采购关键零件、增加标准化产品的国内生产以及加快寻找更具成本效益的材料来降低风险。

本研究报告是商业研究公司 (The Business Research Company) 新报告系列的一部分，该系列提供乳癌液态切片市场统计数据，包括全球市场规模、各地区市场份额、乳癌液态切片市场份额的竞争对手、详细的乳癌液态切片细分市场、市场趋势和商机，以及您在乳癌液态切片行业取得成功所需的乳癌。本乳癌液态切片液态切片研究报告对该行业的现状和未来趋势进行了详细分析，为您提供所需的一切观点。

未来五年的预测成长率为14.5%，较我们先前对该市场的预测略有下降0.2%。下降的主要原因是美国与其他国家之间的关税影响。这项影响将直接影响美国，导致来自美国和丹麦等主要地区的循环肿瘤去氧核糖核酸(DNA) 分离套件和次世代定序的供应链中断，从而可能增加微创癌症检测的成本。

预计未来几年乳癌患者数量的增加将推动乳癌液态切片市场的成长。乳癌是一种在乳腺细胞中发展的恶性肿瘤，通常发生在产乳小叶或将乳汁输送到乳头的乳管中。乳癌发生率的上升归因于遗传易感性、荷尔蒙失调、老化、生活方式改变、肥胖、饮酒、缺乏运动、辐射暴露和环境污染物等因素。乳癌液态切片透过检测血液中的循环肿瘤 DNA (ctDNA) 或循环性肿瘤细胞(CTC) 来发挥治疗作用，从而实现即时疾病监测。这有助于评估治疗效果、检测治疗抗药性并识别标靶治疗的基因突变。例如，根据致力于癌症研究、教育、宣传和患者支持的美国非营利组织美国癌症协会的数据，预计乳癌新患者病例数将从 2024 年的 313,510 例增加到 2025 年的 319,750 例。因此，乳癌发生率的上升正在刺激乳癌液态切片市场的扩张。

乳癌液态切片市场的主要企业正专注于伴随诊断等创新市场发展，透过识别最能从特定治疗方法中获益的患者来促进个人化护理。伴随诊断利用液态切片技术检测生物标记物，例如基因突变、循环肿瘤 DNA (ctDNA) 和指示治疗反应的蛋白质表现。例如，2023 年 1 月，美国生物技术公司 Guardant Health Inc. 的 Guardant360 CDx液态切片测试获得美国食品药物管理局(FDA)核准，可作为美纳里尼集团 ORSERDU (elacestrant) 的伴随诊断，该药物用于治疗携带 ESR1 基因突变的进行性或转移性乳癌患者。此项核准使肿瘤学家能够使用该测试进行全面的基因组分析，并识别可能受益于标靶治疗的患者。此项核准标誌着 Guardant Health 首次获得 FDA核准用于乳癌，并增强了该公司在精准肿瘤学领域的地位。

2024年1月，Guardant Health将与Hikma Pharmaceuticals合作，利用Guardant Health先进的液态切片和组织活体组织切片技术进行早期癌症检测、復发监测和优化治疗方案。此次合作将增强Guardant Health的全球影响力，并缓解中东和北非地区日益增长的癌症负担。 Hikma Pharmaceuticals是一家总部位于英国的製药公司，专注于创新医疗解决方案。

乳癌液态切片市场由提供早期癌症检测、治疗监测、微量残存疾病(MRD) 检测、復发预测和用于标靶治疗选择的基因突变分析等服务的营业单位所获得的收益组成。市场价值还包括服务提供者销售或包含在其服务产品中的相关产品的价值。乳癌液态切片市场还包括循环肿瘤 DNA (ctDNA) 检测试剂套件、循环性肿瘤细胞(CTC) 检测系统、次世代定序仪(NGS) 试剂盒、基于 PCR 的液态切片测试、采血管以及用于非侵入性癌症诊断和监测的消耗品和试剂的销售。此市场的价值代表“出厂价”，即产品製造商或创造者向其他营业单位（包括下游製造商、批发商、经销商和零售商）或直接向最终客户销售的产品价值。该市场中的产品价值还包括产品创造者销售的任何相关服务。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场：宏观经济情景，包括利率、通膨、地缘政治、贸易战和关税，以及新冠疫情和復苏对市场的影响

第五章 全球成长分析与策略分析框架

  • 全球乳癌液态切片：PESTEL分析（政治、社会、技术、环境、法律因素、驱动因素和限制因素）
  • 最终用途产业分析
  • 全球乳癌液态切片市场：成长率分析
  • 全球乳癌液态切片市场表现：规模与成长，2019-2024
  • 全球乳癌液态切片市场预测：规模与成长，2024-2029，2034
  • 全球乳癌液态切片：总目标市场（TAM）

第六章 市场细分

  • 全球乳癌液态切片市场（依产品、绩效及预测），2019-2024 年、2024-2029 年、2034 年
  • 耗材
  • 套件
  • 全球乳癌液态切片市场（依生物标记、绩效及预测），2019-2024 年、2024-2029 年、2034 年
  • 细胞外囊泡（EV）
  • 游离DNA（cfDNA）
  • 循环肿瘤RNA（ctRNA）
  • 循环性肿瘤细胞（CTC）
  • 游离RNA
  • 其他生物标誌物
  • 全球乳癌液态切片市场的应用、表现及预测（2019-2024、2024-2029、2034）
  • 早期检测或筛检
  • 诊断
  • 其他用途
  • 全球乳癌液态切片市场（按最终用户、业绩和预测），2019-2024 年、2024-2029 年、2034 年
  • 研究所
  • 医院
  • 医生检查室
  • 参考实验室
  • 公共卫生研究所
  • 研究所
  • 小分子研究所
  • 病理实验室
  • 全球乳癌液态切片市场：按耗材（类型）细分、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 试剂
  • 聚合酵素链锁反应（PCR）检测
  • 序列面板
  • 样本收集管
  • 全球乳癌液态切片市场：按试剂套件类型、性能和预测细分，2019-2024 年、2024-2029 年、2034 年
  • 基于DNA的液态生物检体套件
  • 基于RNA的液态生物检体套件
  • 多标记液态生物检体套件

第七章 区域和国家分析

  • 全球乳癌液态切片市场：按地区、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 全球乳癌液态切片市场：国家、绩效及预测（2019-2024、2024-2029、2034）

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章：澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章 西欧市场

第十六章英国市场

第十七章：德国市场

第18章：法国市场

第十九章：义大利市场

第20章：西班牙市场

第21章 东欧市场

第22章俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第30章：竞争格局与公司概况

  • 乳癌液态切片市场：竞争格局
  • 乳癌液态切片市场：公司简介
    • Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
    • Roche Diagnostics Overview, Products and Services, Strategy and Financial Analysis
    • Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
    • Thermo Fisher Scientific Overview, Products and Services, Strategy and Financial Analysis
    • Siemens Healthineers Overview, Products and Services, Strategy and Financial Analysis

第31章：其他领先和创新企业

  • Agilent Technologies Inc.
  • Illumina Inc.
  • Sysmex Corporation
  • Qiagen NV
  • Myriad Genetics Inc.
  • NeoGenomics Laboratories
  • Guardant Health Inc.
  • Twist Bioscience
  • Foundation Medicine Inc.
  • Biodesix Inc.
  • Menarini Silicon Biosystems
  • Datar Cancer Genetics
  • Abcam plc
  • OncoDNA SA
  • Genomic Health Inc.

第 32 章全球市场竞争基准化分析与仪表板

第33章 重大併购

第34章近期市场趋势

第 35 章：高潜力市场国家、细分市场与策略

  • 2029年乳癌液态切片市场：哪些国家将提供新机会
  • 2029年乳癌液态切片市场：细分领域带来新机会
  • 2029年乳癌液态切片市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手策略

第36章 附录

简介目录
Product Code: r33985u

A breast cancer liquid biopsy is a minimally invasive test that detects and analyzes tumor-derived materials in a patient's blood or other bodily fluids, offering valuable insights into the presence, progression, and genetic profile of breast cancer without the need for a traditional tissue biopsy.

The primary products used in breast cancer liquid biopsy include consumables and kits. Consumables refer to disposable materials, reagents, and kits utilized in liquid biopsy tests to detect and analyze biomarkers associated with breast cancer. The key biomarkers include extracellular vesicles (EVs), cell-free DNA (cfDNA), circulating tumor RNA (ctRNA), circulating tumor cells (CTCs), cell-free RNA (cfRNA), and others. These biomarkers are applied in early detection or screening, diagnosis, and other purposes. The end users of breast cancer liquid biopsy encompass laboratories, hospitals, physician laboratories, reference laboratories, public health laboratories, research institutes, small molecular laboratories, and pathology laboratories.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp increase in U.S. tariffs and resulting trade tensions in spring 2025 are significantly impacting the medical equipment sector, especially for imported components used in imaging machines, surgical-grade stainless steel, and disposable plastics. With hospitals and clinics pushing back against price increases, manufacturers are facing margin pressure. The situation is further complicated by regulatory challenges, as switching suppliers due to tariffs often necessitates re-certification of medical devices, leading to delays in market entry. In response, companies are mitigating risks by dual-sourcing key components, ramping up domestic production of standardized items, and accelerating research into more cost-effective materials.

The breast cancer liquid biopsy market research report is one of a series of new reports from The Business Research Company that provides breast cancer liquid biopsy market statistics, including breast cancer liquid biopsy industry global market size, regional shares, competitors with a breast cancer liquid biopsy market share, detailed breast cancer liquid biopsy market segments, market trends and opportunities, and any further data you may need to thrive in the breast cancer liquid biopsy industry. This breast cancer liquid biopsy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The breast cancer liquid biopsy market size has grown rapidly in recent years. It will grow from $0.78 billion in 2024 to $0.89 billion in 2025 at a compound annual growth rate (CAGR) of 14.2%. The growth in the historic period can be attributed to advancements in next-generation sequencing (ngs), increasing prevalence of breast cancer, growing demand for non-invasive diagnostic methods, rising adoption of personalized medicine, and increased funding for cancer research.

The breast cancer liquid biopsy market size is expected to see rapid growth in the next few years. It will grow to $1.53 billion in 2029 at a compound annual growth rate (CAGR) of 14.5%. The growth in the forecast period can be attributed to technological advancements in liquid biopsy assays, increasing adoption of liquid biopsy in early cancer screening, rising demand for real-time cancer monitoring, expanding applications in precision oncology, growing investments in liquid biopsy research and development. Major trends in the forecast period include integration of artificial intelligence in liquid biopsy analysis, advancements in single-cell sequencing, development of multi-omics liquid biopsy platforms, improvement in liquid biopsy sensitivity and specificity, and adoption of digital pcr for ultra-precise mutation detection.

The forecast of 14.5% growth over the next five years indicates a slight reduction of 0.2% from the previous estimate for this market.This reduction is primarily due to the impact of tariffs between the US and other countries. This is likely to directly affect the US through supply chain disruptions for circulating tumor deoxyribonucleic acid (DNA) isolation kits and next-generation sequencing reagents, sourced from key regions such as China and Denmark, which could lead to increased costs for minimally invasive cancer detection.The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising number of breast cancer cases is expected to drive the growth of the breast cancer liquid biopsy market in the coming years. Breast cancer is a malignancy that originates in the breast cells, typically in the milk-producing lobules or the ducts that transport milk to the nipple. The increasing prevalence of breast cancer is attributed to factors such as genetic predisposition, hormonal imbalances, an aging population, lifestyle changes, obesity, alcohol consumption, physical inactivity, radiation exposure, and environmental pollutants. Breast cancer liquid biopsy plays a crucial role in treatment by detecting circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) in the blood, enabling real-time disease monitoring. It helps assess treatment response, detect therapy resistance, and identify genetic mutations for targeted therapies. For example, according to the American Cancer Society, a US-based nonprofit organization dedicated to cancer research, education, advocacy, and patient support, new breast cancer cases are projected to increase from 313,510 in 2024 to 319,750 in 2025. As a result, the growing incidence of breast cancer is fueling the expansion of the breast cancer liquid biopsy market.

Leading companies in the breast cancer liquid biopsy market are focusing on innovative developments, such as companion diagnostics, to facilitate personalized treatment by identifying patients who are most likely to benefit from specific therapies. Companion diagnostics leverage liquid biopsy technology to detect biomarkers, including genetic mutations, circulating tumor DNA (ctDNA), and protein expressions that indicate treatment responsiveness. For instance, in January 2023, Guardant Health Inc., a US-based biotechnology company, received Food and Drug Administration (FDA) approval for its Guardant360 CDx liquid biopsy test as a companion diagnostic for Menarini Group's ORSERDU (elacestrant), a therapy for advanced or metastatic breast cancer patients with ESR1 mutations. This approval allows oncologists to conduct comprehensive genomic profiling using the test, enabling them to identify patients who may benefit from targeted therapy. It also marks Guardant Health's first FDA approval for breast cancer, strengthening its presence in precision oncology.

In January 2024, Guardant Health Inc. partnered with Hikma Pharmaceuticals plc to enhance early cancer detection, monitor recurrence, and optimize treatment selection using Guardant Health's advanced liquid and tissue biopsy technologies. This collaboration strengthens Guardant Health's global presence and addresses the increasing cancer burden in the Middle East and North Africa. Hikma Pharmaceuticals plc is a UK-based pharmaceutical company specializing in innovative healthcare solutions.

Major players in the breast cancer liquid biopsy market are Johnson & Johnson Private Limited, Roche Diagnostics, Merck KGaA, Thermo Fisher Scientific, Siemens Healthineers, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Qiagen N.V., Myriad Genetics Inc., NeoGenomics Laboratories, Guardant Health Inc., Twist Bioscience, Foundation Medicine Inc., Biodesix Inc., Menarini Silicon Biosystems, Datar Cancer Genetics, Abcam plc, OncoDNA SA, Genomic Health Inc., RainDance Technologies, Biocept Inc., Fluxion Biosciences Inc., Angle plc.

North America was the largest region in the breast cancer liquid biopsy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in breast cancer liquid biopsy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the breast cancer liquid biopsy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The breast cancer liquid biopsy market consists of revenues earned by entities by providing services such as early cancer detection, treatment monitoring, minimal residual disease (MRD) detection, recurrence prediction, and genetic mutation analysis for targeted therapy selection. The market value includes the value of related goods sold by the service provider or included within the service offering. The breast cancer liquid biopsy market also includes sales of circulating tumor DNA (ctDNA) assay kits, circulating tumor cell (CTC) detection systems, next-generation sequencing (NGS) panels, PCR-based liquid biopsy tests, blood collection tubes, and consumables and reagents used for non-invasive cancer diagnostics and monitoring. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Breast Cancer Liquid Biopsy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on breast cancer liquid biopsy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for breast cancer liquid biopsy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The breast cancer liquid biopsy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Product: Consumables; Kits
  • 2) By Biomarkers: Extracellular Vesicles (EVs); Cell-free DNA (cfDNA); Circulating Tumor RNA (ctRNA); Circulating Tumor Cells (CTCs); Cell-free RNA (cfRNA); Other Biomarkers
  • 3) By Application: Early Detection Or Screening; Diagnosis; Other Applications
  • 4) By End Users: Laboratories; Hospitals; Physician Laboratories; Reference Laboratories; Public Health Laboratories; Research Institutes; Small Molecular Laboratories; Pathology Laboratories
  • Subsegments:
  • 1) By Consumables: Reagents; Polymerase Chain Reaction (PCR) Assays; Sequencing Panels; Sample Collection Tubes
  • 2) By Kits: DNA-based Liquid Biopsy Kits; RNA-based Liquid Biopsy Kits; Multi-marker Liquid Biopsy Kits
  • Companies Mentioned: Johnson & Johnson Private Limited; Roche Diagnostics; Merck KGaA; Thermo Fisher Scientific; Siemens Healthineers; Agilent Technologies Inc.; Illumina Inc.; Sysmex Corporation; Qiagen N.V.; Myriad Genetics Inc.; NeoGenomics Laboratories; Guardant Health Inc.; Twist Bioscience; Foundation Medicine Inc.; Biodesix Inc.; Menarini Silicon Biosystems; Datar Cancer Genetics; Abcam plc; OncoDNA SA; Genomic Health Inc.; RainDance Technologies; Biocept Inc.; Fluxion Biosciences Inc.; Angle plc
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Breast Cancer Liquid Biopsy Market Characteristics

3. Breast Cancer Liquid Biopsy Market Trends And Strategies

4. Breast Cancer Liquid Biopsy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Breast Cancer Liquid Biopsy Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Breast Cancer Liquid Biopsy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Breast Cancer Liquid Biopsy Market Growth Rate Analysis
  • 5.4. Global Breast Cancer Liquid Biopsy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Breast Cancer Liquid Biopsy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Breast Cancer Liquid Biopsy Total Addressable Market (TAM)

6. Breast Cancer Liquid Biopsy Market Segmentation

  • 6.1. Global Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Consumables
  • Kits
  • 6.2. Global Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Extracellular Vesicles (EVs)
  • Cell-free DNA (cfDNA)
  • Circulating Tumor RNA (ctRNA)
  • Circulating Tumor Cells (CTCs)
  • Cell-free RNA (cfRNA)
  • Other Biomarkers
  • 6.3. Global Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Early Detection Or Screening
  • Diagnosis
  • Other Applications
  • 6.4. Global Breast Cancer Liquid Biopsy Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Laboratories
  • Hospitals
  • Physician Laboratories
  • Reference Laboratories
  • Public Health Laboratories
  • Research Institutes
  • Small Molecular Laboratories
  • Pathology Laboratories
  • 6.5. Global Breast Cancer Liquid Biopsy Market, Sub-Segmentation Of Consumables, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Reagents
  • Polymerase Chain Reaction (PCR) Assays
  • Sequencing Panels
  • Sample Collection Tubes
  • 6.6. Global Breast Cancer Liquid Biopsy Market, Sub-Segmentation Of Kits, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • DNA-based Liquid Biopsy Kits
  • RNA-based Liquid Biopsy Kits
  • Multi-marker Liquid Biopsy Kits

7. Breast Cancer Liquid Biopsy Market Regional And Country Analysis

  • 7.1. Global Breast Cancer Liquid Biopsy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Breast Cancer Liquid Biopsy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Breast Cancer Liquid Biopsy Market

  • 8.1. Asia-Pacific Breast Cancer Liquid Biopsy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Breast Cancer Liquid Biopsy Market

  • 9.1. China Breast Cancer Liquid Biopsy Market Overview
  • 9.2. China Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Breast Cancer Liquid Biopsy Market

  • 10.1. India Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Breast Cancer Liquid Biopsy Market

  • 11.1. Japan Breast Cancer Liquid Biopsy Market Overview
  • 11.2. Japan Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Breast Cancer Liquid Biopsy Market

  • 12.1. Australia Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Breast Cancer Liquid Biopsy Market

  • 13.1. Indonesia Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Breast Cancer Liquid Biopsy Market

  • 14.1. South Korea Breast Cancer Liquid Biopsy Market Overview
  • 14.2. South Korea Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Breast Cancer Liquid Biopsy Market

  • 15.1. Western Europe Breast Cancer Liquid Biopsy Market Overview
  • 15.2. Western Europe Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Breast Cancer Liquid Biopsy Market

  • 16.1. UK Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Breast Cancer Liquid Biopsy Market

  • 17.1. Germany Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Breast Cancer Liquid Biopsy Market

  • 18.1. France Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Breast Cancer Liquid Biopsy Market

  • 19.1. Italy Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Breast Cancer Liquid Biopsy Market

  • 20.1. Spain Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Breast Cancer Liquid Biopsy Market

  • 21.1. Eastern Europe Breast Cancer Liquid Biopsy Market Overview
  • 21.2. Eastern Europe Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Breast Cancer Liquid Biopsy Market

  • 22.1. Russia Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Breast Cancer Liquid Biopsy Market

  • 23.1. North America Breast Cancer Liquid Biopsy Market Overview
  • 23.2. North America Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Breast Cancer Liquid Biopsy Market

  • 24.1. USA Breast Cancer Liquid Biopsy Market Overview
  • 24.2. USA Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Breast Cancer Liquid Biopsy Market

  • 25.1. Canada Breast Cancer Liquid Biopsy Market Overview
  • 25.2. Canada Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Breast Cancer Liquid Biopsy Market

  • 26.1. South America Breast Cancer Liquid Biopsy Market Overview
  • 26.2. South America Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Breast Cancer Liquid Biopsy Market

  • 27.1. Brazil Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Breast Cancer Liquid Biopsy Market

  • 28.1. Middle East Breast Cancer Liquid Biopsy Market Overview
  • 28.2. Middle East Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Breast Cancer Liquid Biopsy Market

  • 29.1. Africa Breast Cancer Liquid Biopsy Market Overview
  • 29.2. Africa Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Breast Cancer Liquid Biopsy Market Competitive Landscape And Company Profiles

  • 30.1. Breast Cancer Liquid Biopsy Market Competitive Landscape
  • 30.2. Breast Cancer Liquid Biopsy Market Company Profiles
    • 30.2.1. Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Roche Diagnostics Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Thermo Fisher Scientific Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Siemens Healthineers Overview, Products and Services, Strategy and Financial Analysis

31. Breast Cancer Liquid Biopsy Market Other Major And Innovative Companies

  • 31.1. Agilent Technologies Inc.
  • 31.2. Illumina Inc.
  • 31.3. Sysmex Corporation
  • 31.4. Qiagen N.V.
  • 31.5. Myriad Genetics Inc.
  • 31.6. NeoGenomics Laboratories
  • 31.7. Guardant Health Inc.
  • 31.8. Twist Bioscience
  • 31.9. Foundation Medicine Inc.
  • 31.10. Biodesix Inc.
  • 31.11. Menarini Silicon Biosystems
  • 31.12. Datar Cancer Genetics
  • 31.13. Abcam plc
  • 31.14. OncoDNA SA
  • 31.15. Genomic Health Inc.

32. Global Breast Cancer Liquid Biopsy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Breast Cancer Liquid Biopsy Market

34. Recent Developments In The Breast Cancer Liquid Biopsy Market

35. Breast Cancer Liquid Biopsy Market High Potential Countries, Segments and Strategies

  • 35.1 Breast Cancer Liquid Biopsy Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Breast Cancer Liquid Biopsy Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Breast Cancer Liquid Biopsy Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer